EKF Diagnostics Holdings plc

Equities

EKF

GB0031509804

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 11:35:20 2024-04-24 am EDT			5-day change	1st Jan Change
27.75 ^GBX	+0.54%		+0.73%	-12.32%

Apr. 11	Onward Opportunities' small-cap strategy yields solid results in 2023	AN
Mar. 20	EKF Diagnostics says prospects "promising" but pauses dividends	AN

EKF Diagnostics : New UK supply contract for COVID-19 sample collection kits

August 05, 2020 at 04:42 am EDT

Download the full announcement

New partner from the private sector to usePrimeStore MTM for UK staff testing

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has received an initial order worth £3m from a partner from the private sector to supply PrimeStore MTM, a novel patented sample collection device, to be used in a COVID-19 testing programme for UK staff. This new supply contract is in addition to the $14.1m orders for the three-month period ending 30 September 2020, already disclosed in the 14 July 2020 update, and also covers the period ending 30 September 2020.

With increasing orders for the PrimeStore MTM sample collection device the Company has now established a second UK production line at the Company's facilities in South Wales. EKF now employs 20 new contracting staff members to work on these production lines, which are able to produce 25,000 sample collection tubes a day. Further details on the expansion of manufacturing capacity was provided in the 14 July 2020 update and the Company can confirm that the PrimeStore MTM production line is now up and running in Germany.

The PrimeStore MTM sample collection device, deactivates viruses, bacteria, fungi and mycobacterium tuberculosis allowing safe sample handling and transport, greatly reducing risk of infection. The device was invented in 2006 in preparation for a worldwide pandemic and is designed to de-activate pathogen rapidly and stabilise the RNA for up to four weeks with no requirement for cold storage. In the case of COVID-19, by deactivating the virus testing can now take place outside of containment facilities opening up capacity in more testing laboratories. With the flu season approaching, the PrimeStore MTM can also safely collect flu and COVID-19 samples in the same collection kit.

Due to the continued demand for PrimeStore MTM, full year performance is likely to further exceed, and possibly significantly exceed, previously revised management expectations.

The persons responsible for arranging the release of this Announcement on behalf of the Company are Julian Baines, CEO, and Richard Evans, FD and COO respectively.

Enquiries:

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, Finance Director and COO	www.ekfdiagnostics.com Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker) Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	Tel: 020 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	Tel: 020 7933 8780 or Mob: 07980 541 893 / 07584 391 303

Attachments

Original document
Permalink

Disclaimer

EKF Diagnostics Holdings plc published this content on 05 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2020 08:41:24 UTC

Latest news about EKF Diagnostics Holdings plc

Onward Opportunities' small-cap strategy yields solid results in 2023	Apr. 11	AN
EKF Diagnostics says prospects "promising" but pauses dividends	Mar. 20	AN
EKF Diagnostics Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
EKF Diagnostics reports trading in line with expectations	Jan. 29	AN
EKF Diagnostics Holdings plc Provides Earnings Guidance for the Full Year 2023	Jan. 29	CI
EKF Diagnostics Holdings plc Announces the Official Opening of its New State-Of-The-Art Life Sciences Manufacturing Site in South Bend, Indiana, United States	23-10-26	CI
EARNINGS: FireAngel Safety interim loss widens amid ongoing headwinds	23-09-26	AN
Earnings Flash (EKF.L) EKF DIAGNOSTICS HOLDINGS Reports H1 Revenue GBP26.9M	23-09-26	MT
EKF Diagnostics Holdings plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
FTSE 100 Closes Tuesday Up 0.41% as Oil-Price Rises Benefit the Index	23-09-12	DJ
EKF Diagnostics hires CFO from Trellus Health, latter names successor	23-09-12	AN
FTSE 100 Rises, Led by AB Foods; Smurfit Kappa Slides	23-09-12	DJ
Trellus Health's Interim Finance Head Takes Full-time CFO Role at EKF Diagnostics	23-09-12	MT
EKF Diagnostics Holdings plc Provides Financial Guidance for the Year Ending 31 December 2023	23-09-12	CI
EKF Diagnostics Holdings plc Appoints Stephen Young as Chief Financial Officer	23-09-12	CI
Revolution Bars reports good progress from Peach Pubs	23-07-26	AN
FTSE 100 Closes Down 0.2% as Miners Offset Ocado, -2-	23-07-26	DJ
FTSE 100 Closes Up 0.5% as Sage Group Shines	23-06-28	DJ
SONIA Illiquidity Could Explain Disconnect in BOE Peak Rate Pricing	23-06-28	DJ
EKF Diagnostics says CFO Davies resigns to pursue other opportunities	23-06-28	AN
EKF Diagnostics CFO Plans Exit; Successor to Assume Role in Q4	23-06-28	MT
Marc Davies to Step Down as Chief Financial Officer of EKF Diagnostics Holdings plc	23-06-28	CI
EKF Diagnostics announces enzyme fermenter progress	23-06-20	AN
EKF Diagnostics' Enzyme Fermenter Completes Factory Acceptance Testing	23-06-20	MT
EKF Diagnostics Holdings plc Announces Its Life Sciences Division's New 14,500L Enzyme Fermentation Capacity Expansion Progress	23-06-20	CI

Chart EKF Diagnostics Holdings plc

Duration

Period

More charts

Company Profile

EKF Diagnostics Holdings plc is a United Kingdom-based diagnostics company. The Company is engaged in point-of-care testing, central laboratory tests, enzyme manufacturing and the provision of contract manufacturing services to the healthcare industry. Its principal activity is the development, manufacture and supply of products into the in-vitro diagnostics marketplace. Its point of care analyzers is designed for use within doctors' surgeries, clinics, blood banks and hospital and private laboratories to provide results. Its life sciences specialize in producing enzymes and contracted custom products for use in medical diagnostics, pharmaceuticals and industry. Its life science facilities are based in two locations in Indiana, United States. Its central laboratory division manufactures a spectrum of reagents for use in hospital laboratories. Its contract manufacturing business provides specialized services to the diagnostics and healthcare industries for the production of custom kits.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-14 - Annual General Meeting

More about the company